Studies have shown that active fund managers routinely underperform the S&P500 index*​

Pasithea Therapeutics Corp. (NASDAQ: KTTA)

KTTA Stock Predictions and Ratings

WSX Rating:
NOT AVAILABLE
WSX Forecast (1yr):
NOT AVAILABLE
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
135%

KTTA Stock Analysis

KTTA PE Ratio:

KTTA PEG Ratio: Not Available

KTTA Forward EPS Growth (12 month): 0.00%

KTTA PS Ratio:

KTTA PSG Ratio: Not Available

KTTA Forward Revenue Growth (12 month): 0.00%

KTTA Articles

No data was found